TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients

TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for the treatment of inherited Epidermolysis Bullosa (EB). This trial marks a significant advancement in the quest for effective therapies for this challenging condition.

The Phase 2 trial of AC-203 is a double-blind, intra-individual comparison, proof-of-concept study designed to assess both the efficacy and safety of the drug. It will include patients as young as two years old, underscoring the company’s commitment to addressing the needs of pediatric EB patients. The trial aims to evaluate several key outcomes, including the reduction of lesion surface area and blister frequency, improvement in pruritus and pain, and a decrease in pro-inflammatory cytokines.

Understanding Epidermolysis Bullosa

Epidermolysis Bullosa is a group of genetic disorders characterized by extreme skin fragility and susceptibility to blistering. The condition is categorized into four main types based on the specific cleavage sites within the skin layers: Simplex, Dystrophic, Junctional, and Kindler Syndrome. Recent research suggests that inflammation plays a significant role in the exacerbation of symptoms in various EB subtypes.

Partnership and Drug Development

TWi Biotechnology has partnered with Castle Creek Pharmaceuticals to lead the global clinical development of AC-203 specifically for Epidermolysis Bullosa Simplex. This collaboration aims to leverage Castle Creek’s expertise in advancing treatments for genetic skin disorders.

Calvin Chen, CEO and President of TWi Biotechnology, expressed optimism about the trial, stating, “We are hopeful the unique activities of AC-203 in inhibiting the activation of NLRP3 inflammasome and decreasing the production of pro-inflammatory cytokines, including IL-1beta and IL-18, could reduce the formation of blisters and the severity of skin lesions in EB patients. We are grateful for the support of local EB patient groups, which has been instrumental since the inception of this program.”

Local Support and Patient Perspectives

The launch of this trial has garnered significant support from patient advocacy groups. Se-Meng Cheng, founder and CEO of the Taiwan Debra Home Care Promotion Association, commented, “Because EB is a devastating disease to patients and their caregivers, everyday life can be a struggle, particularly for families with children suffering from EB. An effective treatment that reduces lesions would not only improve physical health but also offer substantial mental and emotional relief. We are excited about TWi Biotechnology’s efforts and look forward to collaborating on this crucial research.”

Currently, there are no approved drug treatments for any type of Epidermolysis Bullosa, and managing the condition often involves meticulous and sometimes traumatic wound care. The initiation of the Phase 2 trial for AC-203 represents a hopeful step toward finding a viable treatment option for EB patients and their families worldwide.